Beskrivelse
Krav
IPC-klasse
Fullmektig i Norge:
Fullmektig i EP:
2010.01.06, US 29261410 P
DE AGOSTINI ET AL: "Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 82, no. 15, 1 August 1985 (1985-08-01), pages 5190-5193, XP055061585, ISSN: 0027-8424 (B1)
EP-A2- 1 288 305 (B1)
J. TANG ET AL: "Expression, Crystallization, and Three-dimensional Structure of the Catalytic Domain of Human Plasma Kallikrein", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 49, 9 December 2005 (2005-12-09), pages 41077-41089, XP055061755, ISSN: 0021-9258, DOI: 10.1074/jbc.M506766200 (B1)
JORG M ET AL: "Kinetic analysis of plasminogen activation by purified plasma kallikren", THROMBOSIS RESEARCH, TARRYTOWN, NY, US, vol. 39, no. 3, 1 August 1985 (1985-08-01) , pages 323-331, XP026360645, ISSN: 0049-3848 [retrieved on 1985-08-01] (B1)
WO-A2-2005/075665 (B1)
SCHNEIDER ET AL: "Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 120, no. 2, 29 July 2007 (2007-07-29) , pages 416-422, XP022171477, ISSN: 0091-6749, DOI: 10.1016/J.JACI.2007.04.028 (B1)
SCHOONBROODT S ET AL: "Human antibodies selected by phage display as potent and selective protease inhibitors", HUMAN ANTIBODIES, vol. 16, no. 1-2, 2007, pages 18-22, XP009169315, & 13TH INTERNATIONAL CONFERENCE ON HUMAN ANTIBODIES AND HYBROMIDAS; MILAN, ITALY; OCTOBER 29 -31, 2007 ISSN: 1093-2607 (B1)
SEXTON DANIEL ET AL: "Discovery and Characterization of a Fully Human Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Treatment of Plasma Kallikrein-Mediated Edema", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 131, no. 2, Suppl. S, February 2013 (2013-02), page AB32, XP009169342, & ANNUAL MEETING OF THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY (AAAAI); SAN ANTONIO, TX, USA; FEBRUARY 22 -26, 2013 (B1)
RASPI G: "Kallikrein and kallikrein-like proteinases: purification and determination by chromatographic and electrophoretic methods", JOURNAL OF CHROMATOGRAPHY B : BIOMEDICAL APPLICATIONS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 684, no. 1, 20 July 1996 (1996-07-20) , pages 265-287, XP004044284, ISSN: 0378-4347, DOI: 10.1016/0378-4347(96)00144-2 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP3459564)
|
Innkommende, AR471787192
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 15. avg. år (EP) | 2024.12.19 | 6310 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 14. avg. år (EP) | 2023.12.21 | 4500 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 13. avg. år (EP) | 2022.12.22 | 4200 | ANAQUA SERVICES | Betalt og godkjent |
Forsinkelsesavgift patent | 2022.02.18 | 700 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 12. avg. år (EP) | 2022.02.18 | 3850 | ANAQUA SERVICES | Betalt og godkjent |
32201760 expand_more expand_less | 2022.01.28 | 5580 | RWS | Betalt |
Gebyr ved bruk av MasterCard-kort
80 = 80 X 1
Valideringsgebyr EP-patent
5500 = 1 X 5500
|